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Abstract The study aimed at assessing the prevalence of
premenstrual symptoms and of premenstrual syndrome
(PMS) and premenstrual dysphoric disorder (PMDD) in a
population-based sample of women of the entire reproduc-
tive age range, as well as to analyse predictors of PMS and
PMDD in terms of socio-demographic, health status and
health behavioural factors. A set of questions on PMS–
based on the premenstrual syndrome screening tool
developed by Steiner et al., translated into German and
piloted—was integrated into the written questionnaire of
the 2007 Swiss Health Survey. Weighted prevalence rates
and multivariable regression analysis for the outcome
variables PMS and PMDD were calculated. A total of
3,913 women aged 15 to 54 years answered the questions
on PMS symptoms, and 3,522 of them additionally
answered the questions on interference of PMS with life.
Ninety one percent of the participants reported at least one
symptom, 10.3% had PMS and 3.1% fulfilled the criteria
for PMDD. The prevalence of PMS was higher in non-
married women, in women aged 35–44 years and in women
of the Italian-speaking region of Switzerland. Both PMS
and PMDD were strongly associated with poor physical
health and psychological distress. Socio-cultural factors
seem to determine the prevalence, perception and handling
of PMS. Considering the association with poor physical
health and high psychological distress, a broader underlying
vulnerability in women qualifying for PMDD must be
assumed and should be taken into account in clinical
management as well as in future research in this field.
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Introduction
Premenstrual symptoms are common in women of repro-
ductive age. It is estimated that up to 30% of women feel
considerably bothered by premenstrually experienced
symptoms, and that for 3–8%, impairment due to dysphoric
symptoms is so severe that they qualify for premenstrual
dysphoric disorder (PMDD) as classified in DSM-IV
(Woods et al. 1982; Johnson 1987; Rivera-Tovar and Frank
1990; Ramcharan et al. 1992; Merikangas et al. 1993;
Sveindottir and Backstrom 2000; Angst et al. 2001;
Wittchen et al. 2002; Halbreich et al. 2003). While PMDD
is well defined, the criteria for the less pronounced
manifestations of premenstrual syndrome (PMS) are less
distinct. As a consequence, prevalence rates for PMDD
have been quite consistent in epidemiological studies and
surveys, whereas rates for PMS vary considerably depend-
ing on study design and instruments used (Woods et al.
1982; Johnson et al. 1988; Rivera-Tovar and Frank 1990;
Ramcharan et al. 1992; Gehlert and Hartlage 1997; Hylan
et al. 1999; Sveindottir and Backstrom 2000; Chawla et al.
2002; Cohen et al. 2002; Wittchen et al. 2002). Also, most
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information stems from community-based samples in the
United States of America, while only a very limited number
of studies have been conducted in Europe and Asia.
Wittchen et al.’s study on a German community-based
sample was limited to young women aged 14 to 24 years,
and Angst et al.’s Zurich cohort study did not focus
specifically on PMS, but assessed perimenstrual symptoms
in a relatively small sample of 299 women aged 28 to
35 years (Angst et al. 2001; Wittchen et al. 2002).
Therefore, population-based information for European
countries still has to be confirmed.
Despite the considerable prevalence and impact of PMS,
which make it even a popular topic in the media (especially
in the USA), the World Health Report on mental health of
2001, listing as many as 2,000 disability rates for about 90
disorders, did not even mention PMS/PMDD (World Health
Organisation 2001). This may reflect the fact that many
professionals are still unaware of the impact of PMS on
individuals, their families and environment (Halbreich et al.
2003). The few reports including work or family impair-
ment show that PMS and PMDD most importantly
influence marital relationships, housework and also—
although to a lower degree—work productivity and work
absenteeism (Kuczmierczyk et al. 1992; Hylan et al. 1999;
Chawla et al. 2002). Assessing PMS and PMDD in
population-based health surveys not only provides the
opportunity to determine the prevalence rates of PMS and
PMDD, but also to assess their associations with socio-
economic and health factors, yielding a better understand-
ing of such determinants and thus contributing to a better
awareness, detection and treatment of these conditions.
So far, an association between PMS/PMDD and health
factors such as smoking status and higher BMI could be
identified, and according to Wittchen et al., women with
PMDD had a high use of general and mental health services
(Cohen et al. 2002; Wittchen et al. 2002; Masho et al. 2005;
Potter et al. 2009). Concerning associations of PMS/PMDD
with socio-demographic factors such as age, education and
employment status, as well as with oral contraceptive (OC)
use, the results of previous research are limited or not
consistent (Cohen et al. 2002; Kurshan and Neill Epperson
2006; Takeda et al. 2006; Potter et al. 2009)
A prospective daily charting of symptoms, the clinical
“gold standard” of the diagnosis of PMS/PMDD cannot be
obtained in a health survey. However, the “Premenstrual
Symptoms Screening Tool” (PSST), a screening instrument
for severe PMS/PMDD developed by Steiner et al., offers a
valuable alternative to such prospective assessments. It is
based on DSM-IV criteria, tested in more than 500 women
and yielded prevalence rates of PMS/PMDD that are
comparable with those of several large studies assessing
PMS/PMDD with prospective daily charting of symptoms
(Steiner et al. 2003).
Based on these considerations, we aimed to assess the
prevalence of premenstrual symptoms and of PMS and
PMDD in a population-based sample of women spanning
the entire reproductive age range. Furthermore, we wanted
to analyse predictors of PMS and PMDD in terms of socio-
demographic, health status and health behavioural factors.
Methods
Data and study population
The 2007 Swiss Health Survey was the fourth nationwide
survey conducted every 5 years by the Swiss Federal Office
of Statistics. The survey assessed detailed information on
health status, health care utilisation and health-related
behaviour. Data were collected from a random sample of
persons aged 15 years and older living in Switzerland and
speaking at least one of three interview languages (German,
French or Italian). Subjects were asked to participate in a
telephone interview and subsequently to fill in a written
questionnaire. The participation rate of the telephone
interview in 2007 was 66% (8,424 men and 10,336
women). Of these, 77% returned the written questionnaire
(6,308 men and 8,085 women).
The questions on premenstrual syndrome used in this
paper were part of the written questionnaire. Only women
aged 15 to 54 years were asked the respective questions on
PMS. The screening tool (PSST) developed and described
in detail by Steiner et al. was previously translated into
German and pre-tested in 80 women, of whom 11 were
patients with physician-diagnosed PMS or PMDD and 69
were healthy women (Steiner et al. 2003). The instrument
included ten items with different premenstrual symptoms,
each of which had to be rated with respect to the presence
and intensity previous to and at the onset of the menstrual
period. The symptom list was introduced with the question
“Do you experience some or any of the following
premenstrual symptoms which start before your period
and stop within a few days of bleeding?” The list included
the symptoms (1) anger/irritability, (2) anxiety/tension, (3)
tearfulness/increased sensitivity to rejection, (4) depressed
mood/hopelessness, (5) difficulty concentrating, (6) fatigue/
lack of energy, (7) overeating/food cravings, (8) insomnia
or hypersomnia, (9) feeling overwhelmed or out of control
and (10) physical symptoms such as breast tenderness,
headaches, joint/muscle pain, bloating and weight gain. The
tool furthermore asked whether such premenstrual symp-
toms interfered not at all, mildly, moderately or severely
with (a) work efficiency, (b) relationships with co-workers
or family, (c) social life activities and (d) home responsi-
bilities. Due to restrictions with regard to the number of
items that could be included in the Health Survey
S. Tschudin et al.486
instrument, some of the PMS questions were dropped
(decreased interest) or merged into one question (insomnia
and hypersomnia, as well as the questions on interference
of symptoms with relationships with co-workers and with
family).
For diagnosing moderate to severe PMS and PMDD, the
instructions of the premenstrual symptoms screening tool of
Steiner et al. were followed: For PMDD/moderate to severe
PMS, at least one of the symptoms (1) to (4) had to be
severe/moderate to severe, at least four of the symptoms (1)
to (10) had to be moderate to severe and one of the
interferences (a), (b), (c) and (d) had to be severe/moderate
to severe (Steiner et al. 2003).
Statistical analyses
Prevalence rates were calculated for each of the single
premenstrual symptoms, for their interference with life, as
well as for “moderate to severe PMS” and PMDD.
Prevalence rates were weighted for the Swiss population,
taking into account the particularities of the sampling
strategy with regard to age, sex, nationality and living
region (oversampling of some population segments had
been done, such as for the Italian language region, in order
to have sufficient sample sizes for region-specific health
reporting; Calmonte et al. 2005).
Multivariable logistic regression analyses were con-
ducted for the outcomes PMS and PMDD separately. We
first performed regression analyses separately with groups
of socio-demographic variables, health behaviour factors,
health status indicators and oral contraception. We then
performed the multivariable regressions, including in an
overall model all those variables, which were significant in
the sub-models at a p level of <0.05. The model including
oral contraceptives was calculated separately since only
women up to age 49 had to answer the questions on
contraception.
As socio-demographic variables, we included age
(10 years groups from 15 to 54 years), marital status
(married, unmarried, widowed and separated/divorced),
nationality (Swiss, Italian, as the largest group of non-
Swiss, and “others”, including French, Spanish, Portuguese,
former Yugoslavian and Turkish nationalities), language
regions (German, French and Italian), education (university
degree, college, secondary school, compulsory school, i.e.,
8 years of education) and employment (full time, part time,
no employment).
Health behaviour consisted of BMI (low<18.5, normal
18.5<25, high≥25<30, very high≥30), physical activity (a
score composed of different variables assessing the fre-
quency and intensity of weekly physical activity and
grading the activity as active, partially active, inactive),
alcohol consumption (intake of pure alcohol per day and
person, no consumption at all to less than once a month;
mild consumption, up to 20 g day−1; moderate to severe
consumption, ≥20 g day−1), smoking status (never smoker,
ex-smoker, current smoker), psychotropic drug consump-
tion within the last 7 days (no consumption, analgesics,
antidepressants only, benzodiazepine only, antidepressants
and benzodiazepine).
The group of health indicators included psychological
distress and physical symptoms. Psychological distress was
assessed by the Mental Health Inventory/Index, a compo-
nent of MOS SF-36 that consists of a grading as none,
moderate and severe of the five following items within the
last 4 weeks: “have been a very nervous person”, “have felt
so down in the dumps that nothing could cheer up”, “had
felt calm and peaceful”, “had felt downhearted and blue”
and “had been a happy person” (Ware and Gandek 1998).
Physical symptoms were assessed by a score based on the
presence of backache, abdominal pain, headache, weakness,
diarrhoea/constipation, sleep disturbance, palpitations and
chest pain within the last 4 weeks and was graded as none,
moderate or severe (Weiss et al. 1990). The statistical
analysis was conducted using STATA/SE 8.0. Statistical
significance was considered at p<0.05.
Results
A total of 3,913 women aged 15 to 54 years completed the
questions on PMS symptoms, 3,522 of them also answered
the questions on the interference of PMS with life. The
weighted prevalence rates of the single premenstrual
symptoms by degree of severity are shown in Table 1.
Fifty seven percent of the women reported having at least a
mild degree of “anger/irritability” or “tearfulness/mood
swings”, two of the four core symptoms of PMDD, and
about the same proportion reported “fatigue/lack of ener-
gy”. Almost three quarters indicated having physical
symptoms, such as breast tenderness, headaches, joint/
muscle pain, bloating and weight gain. Overall, 91% had at
least one symptom of any degree of severity. The median
duration of symptoms was 3 days, 90% indicated a time
range of 5 days or less. Women felt most bothered in their
relationship with co-workers and/or family (Table 2) and
6.4% reported severe interference of at least one symptom.
In Table 3, the weighted prevalence rates of PMS and
PMDD are displayed by degree of severity and by several
socio-demographic, health behaviour and health status
factors, as well as by use of oral contraception (n=3,522).
From those women who provided information on both
symptom severity as well as interference, 362 (14.46
unweighted and 10.30% weighted prevalence) had moder-
ate to severe PMS and 111 (3.15% unweighted and 3.10%
weighted) fulfilled the criteria for PMDD.
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The results from the multivariable regression analyses
are shown in Table 4. With regard to socio-demographic
characteristics, PMS was associated with age (OR 1.64,
95% CI 1.07–2.52 for women aged 35–44 years), marital
status (OR 1.44, 95% CI 1.05–1.96 for non-married
women) and living region (OR 1.54, 95% CI 1.01–2.34
for women of the Italian-speaking region). While in the
sub-models elevated ORs were also seen for women of the
French speaking region and for unemployed women, these
associations were no longer significant in the overall model,
pointing to confounding. No associations were seen
between socio-demographic variables and PMDD.
Health indicators were significantly associated with PMS
and with PMDD. The increase of the odds ratios was more
pronounced for severe physical symptoms and psycholog-
ical distress than for those of moderate degree. The
association between moderate physical symptoms and
PMDD was not significant, probably due to a too low
number of affected women.
Among the health behaviour variables, PMS was
associated with former smoking (OR 1.67, 95% CI 1.22–
2.27) and with self-reported use of psychotropic drugs,
namely intake of analgesics (OR 1.44, 95% CI 1.08–1.93)
and benzodiazepines (OR 2.5, 95% CI 1.44–4.34). PMS
was less likely in women using oral contraceptives (OR
0.61, 95% CI 0.40–0.93). Significant associations were
seen in the sub-models also for antidepressants and for the
combinations of antidepressants and benzodiazepines, but
disappeared in the overall model, pointing again to
confounding. None of the health behaviour predictors were
associated with PMDD.
Discussion
In this population-based sample of 3,913 women of the
whole reproductive age in Switzerland, 91% reported at
least one premenstrual symptom. Of all participants 10.3%
had PMS according to the DSM-IV criteria-based definition
of Steiner and 3.1% fulfilled the criteria for PMDD. The
prevalence of PMS was higher in non-married women, in
women aged 35–44 years and in women of the Italian-
speaking region. It was furthermore associated with
psychotropic drug use and was less likely in women using
oral contraception. Both PMS and PMDD were strongly
associated with poor physical health and psychological
distress.
Prevalence
The 91% prevalence of any PMS symptom is in line with
the results of previous studies, which have identified
symptom prevalence rates of 75–95% (Johnson et al.
1988; Wilson and Keye 1989; Hylan et al. 1999; Wittchen
et al. 2002; Perkonigg et al. 2004; Takeda et al. 2006;
Vichnin et al. 2006; Campagne and Campagne 2007). The
Not at all (%) Mild (%) Moderate (%) Severe (%)
Work efficiency 56.5 31.3 9.5 2.7
Relationships with co-workers or family 48.5 35.9 11.7 3.8
Social life activities 63.3 27.3 7.5 1.9
Home responsibilities 60.3 28.9 8.0 2.9
Table 2 Weighted prevalence
rates of interference of premen-
strual symptoms with work,
relationships, social life and
home responsibilities (n=3,522)
Table 1 Weighted prevalence rates of premenstrual symptoms by degree of severity (n=3,913)
Not at all (%) Mild (%) Moderate (%) Severe (%)
Anger or irritability 43.0 30.4 18.8 7.8
Anxiety or tension 72.7 15.5 9.3 2.5
Tearfulness or mood swings 42.9 29.3 18.3 9.4
Depressed mood 69.2 17.0 10.1 3.7
Difficulty concentrating 82.1 11.9 4.5 1.5
Fatigue or lack of energy 42.1 33.6 16.2 8.1
Overeating or food cravings 58.6 19.8 12.8 8.8
Insomnia or hypersomnia 71.7 14.9 9.2 4.2
Feeling overwhelmed or out of control 88.3 7.2 3.1 1.5
Physical symptoms: breast tenderness, headaches,
joint/muscle pain, bloating, weight gain
26.1 27.2 26.9 19.8
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Table 3 Weighted prevalence rate of PMS/PMDD by degree of severity and by socio-demographic factors, health status and health behaviour
(n=3,522)
Total n (%) No/mild PMS (%)a Moderate to severe PMS (%)a PMDD (%)a
Overall 86.6 10.3 3.1
Socio-demographic factors
Age (years)
15–24 562 (16.0) 86.3 10.7 3.0
25–34 909 (25.8) 89.2 8.6 2.2
35–44 1,376 (39.1) 85.3 11.2 3.5
45–54 675 (19.1) 85.5 10.8 3.7
Marital status
Married 1,705 (48.5) 87.1 9.6 3.3
Unmarried 1,427 (40.5) 86.3 11.0 2.7
Widowed 35 (1.0) 78.6 8.9 12.5
Separated/divorced 353 (10.0) 85.3 11.3 3.4
Nationality
Swiss 3,059 (86.8) 87.7 9.4 2.9
Italian 73 (2.1) 83.8 8.4 7.8
Other 390 (11.1) 83.3 13.7 3.0
Speaking regions
German 2,131 (60.5) 88.2 9.4 2.4
French 1,133 (32.2) 83.3 12.3 4.4
Italian 258 (7.3) 81.0 13.1 5.9
Education
University degree 995 (28.3) 87.3 10.5 2.2
College 220 (6.2) 85.9 11.7 2.4
Secondary school 2,953 (58.3) 86.8 9.8 3.4
Compulsory school 254 (7.2) 83.9 11.9 4.2
Employment
Full time 1,047 (30.7) 88.1 10.2 1.7
Part time 1,607 (47.1) 87.7 9.1 3.2
No employment 760 (22.2) 82.3 13.0 4.7
Health behaviour factors
BMI
Normal (≥18.5<25) 2,544 (72.8) 86.9 10.5 2.6
Low (<18.5) 253 (7.2) 86.7 6.5 6.8
High (≥25<30) 502 (14.4) 87.4 9.3 3.3
Very high (≥30) 195 (5.6) 82.2 13.8 4.0
Physical activity
Active 1,391 (39.5) 87.6 10.1 2.3
Partially active 1,728 (49.1) 86.8 10.0 3.2
Inactive 402 (11.4) 82.6 11.9 5.5
Alcohol consumption
No consumption 1,081 (30.7) 85.5 10.6 3.9
Mild consumption 2,300 (65.4) 87.0 10.4 2.6
Moderate to severe consumption 137 (3.9) 89.4 6 4.6
Smoking status
No smoker 1,904 (54.1) 88.1 9.4 2.5
Ex-smoker 602 (17.1) 82.3 13.1 4.6
Current smoker 1,016 (28.8) 85.9 10.7 3.4
Prevalence and predictors of premenstrual syndrome 489
most common complaints in our study were physical
symptoms, which were reported by 74% of women,
followed by “fatigue/lack of energy” in 68% and “tearfulness/
mood swings” and “anger/irritability” in 67% each. These
findings are also approximately concordant with previous
findings. In the prospective-longitudinal survey of Wittchen
et al., the five most frequently reported symptoms were
physical complaints (44.9%), affect lability (41.7%), fatiga-
bility (36.6%), depressed mood (31.4%) and appetite/craving
(30.3%). In Takeda et al.’s study, physical symptoms were
reported by 81.2%, “anger and irritability” by 70.6% and
“anxiety and tension” by 68.5%. The most prevalent
psychological symptom in the Zurich cohort study was
irritability (49.3%).
The prevalence of moderate to severe PMS in our study
was 14.5% (unweighted) and 10.3% (weighted), respec-
tively, pointing to the association of PMS with socio-
demographic factors that were part of the sampling strategy.
This prevalence rate is lower than the rate of 20.7%
detected by Steiner et al. using the PSST, the screening
instrument, on which our set of questions was based
(Steiner et al. 2003). Steiner et al.’s sample, however, was
from a primary care facility and was not community-based.
Furthermore, the lower number of symptom items included
in our questionnaire may have led to a slight underestima-
tion of the prevalence. The rate in our study lies in between
the prevalence of 5.3% detected by Takeda et al. in a
Japanese sample and 31% found by Vichnin et al. in a U.S.-
American sample of adolescents and is close to the rate of
13.6% found by Angst et al. in the Zurich cohort study
(Angst et al. 2001; Takeda et al. 2006; Vichnin et al. 2006).
In previous studies assessing the PMDD by means of DSM-
IV criteria, the range of prevalence rates was 1–8% (6.4%
in The Harvard Study of Moods and Cycles by Cohen et al.
including 4,164 older premenopausal women, 5.8% over
12 months and 7.4% over lifetime in Wittchen et al.’s
prospective-longitudinal community-based study, 5.1% in
Steiner et al.’s Canadian survey on a sample attending a
primary care facility and 1.2% in the Japanese sample
examined by Takeda et al.). A recently published prospec-
tive study on a randomly selected group of urban and rural
women in the USA found a prevalence as low as Takeda et
al.’s, when strictly claiming that all four diagnostic criteria
had to be considered (Gehlert et al. 2009). In the Zurich
cohort study, the prevalence of “severe PMS” was 8.1%,
but since diagnostic criteria were not consistent with DSM-
IV, comparison is problematic. A prevalence of PMDD of
3.1% in the Swiss female population is on the lower side of
the observed range. There were, however, significant
differences between the three speaking regions with regard
to the prevalence of PMDD as well as PMS: the prevalence
was highest in the Italian, lower in the French and lowest in
the German-speaking region. Cultural influences on per-
ception of PMS related to socio-cultural background have
been discussed in the literature, pointing to differences in
vulnerability of various ethnic groups and to a diversity of
illness beliefs (van den Akker et al. 1995). Furthermore, a
traditional gender role orientation was found to be
Table 3 (continued)
Total n (%) No/mild PMS (%)a Moderate to severe PMS (%)a PMDD (%)a
Psychotropic drug consumption
No consumption 2,570 (73.0) 88.3 9.1 2.6
Analgesics 718 (20.4) 86.1 11.0 2.9
Antidepressants only 77 (2.2) 76.4 16.3 7.3
Benzodiazepines only 103 (2.9) 65.8 31.8 2.4
Antidepressants and benzodiazepines 53 (1.5) 57.2 15.6 27.2
Health status factors
Psychological distress
None 2,783 (79.5) 90.0 8.3 1.7
Moderate 547 (15.6) 78.3 15.9 5.8
Severe 173 (4.9) 63.8 19.4 16.8
Physical symptoms
None 954 (29.7) 92.9 5.7 1.4
Moderate 1,271 (39.5) 87.2 10.8 2.0
Severe 990 (30.8) 81.8 13.3 4.9
Oral contraception
No 1,446 (71.1) 84.3 11.3 4.4
Yes 589 (28.9) 89.4 8.4 2.2
a As prevalence rates are weighted no indication of numbers
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Table 4 Socio-demographic, health behaviour and health status factors associated with PMS and PMDD (multivariable regression analyses with
groups of predictors and overall model)
Models including only groups of predictors Overall model
OR (95% CI) OR (95% CI)
PMS PMDD PMS (n=3,002) PMDD (n=3,094)
Age (years)
15–24 1 1 1 1
25–34 1.21 (0.81–1.82) 0.96 (0.46–2.02) 1.20 (0.79–1.84) 0.76 (0.34–1.67)
35–44 1.57* (1.04–2.37) 1.24 (0.60–2.58) 1.64* (1.07–2.52) 1.18 (0.54–2.56)
45–54 1.36 (0.85–2.16) 1.09 (0.48–2.46) 1.28 (0.78–2.09) 0.79 (0.32–1.95)
Marital status
Married 1 1 1 1
Unmarried 1.48* (1.09–2.01) 1.20 (0.68–2.12) 1.44* (1.05–1.96) 0.98 (0.55–1.75)
Widowed 0.39 (0.05–2.93) 1.28 (0.17–9.8) 0.35 (0.05–2.67) 1.39 (0.17–11.19)
Separated/divorced 1.03 (0.67–1.58) 1.16 (0.57–2.37) 0.90 (0.57–1.41) 0.81 (0.38–1.71)
Nationality
Swiss 1 1
Italian 0.86 (0.38–1.92) 1.39 (0.48–4.02)
Other 1.36 (0.97–1.90) 0.82 (0.42–1.62)
Speaking regions
German 1 1 1 1
French 1.28* (1.01–1.63) 1.58* (1.05–2.39) 1.11 (0.85–1.44) 1.30 (0.82–2.07)
Italian 1.69** (1.14–2.50) 2.07* (1.09–3.92) 1.54* (1.01–2.34) 1.59 (0.77–3.32)
Education
Compulsory school 1 1
Secondary school 1.20 (0.73–1.95) 0.74 (0.27–2.02)
College 1.08 (0.83–1.41) 1.23 (0.76–1.98)
University degree 0.74 (0.43–1.25) 1.43 (0.67–3.09)
Employment
Full time 1 1 1 1
Part time 1.13 (0.85–1.50) 1.81* (1.05–3.12) 1.02 (0.75–1.38) 1.62 (0.90–2.91)
No Employment 1.56** (1.12–2.18) 2.28** (1.25–4.18) 1.30 (0.92–1.85) 1.44 (0.75–2.76)
Oral contraceptiona
No 1 1 1 1
Yes 0.79 (0.57–1.10) 0.59 (0.32–1.10) 0.61* (0.40–0.93)a 0.52 (0.25–1.08)a
Psychological distress
None 1 1 1 1
Moderate 1.43* (1.06–1.94) 2.35*** (1.40–3.96) 1.44* (1.05–1.97) 2.41*** (1.42–4.09)
Severe 2.43*** (1.54–3.83) 6.62*** (3.64–12.05) 2.17** (1.32–3.56) 6.65*** (3.41–12.97)
Physical symptoms
None 1 1 1 1
Moderate 1.56** (1.14–2.15) 1.89*** (0.94–3.80) 1.55** (1.11–2.16) 1.84 (0.91–3.72)
Severe 2.03*** (1.45–2.84) 2.51*** (1.23–5.09) 1.79*** (1.25–2.57) 2.28* (1.10–4.72)
BMI
Normal (≥18.5<25) 1 1
Low (<18.5) 0.63 (0.38–1.03) 1.49 (0.77–2.88)
High (≥25<30) 0.77 (0.55–1.07) 1.22 (0.73–2.05)
Very high (≥30) 0.92 (0.57–1.49) 0.83 (0.35–1.98)
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associated with higher premenstrual distress (Anson 1999).
We speculate that such factors may contribute to the higher
rates in women living in one of the two Romance languages
speaking regions.
Predictors
Socio-demographic factors
In previous research, associations between socio-
demographic factors and PMS/PMDD are not consistent.
In our study, PMS/PMDD was more prevalent in women of
advanced reproductive age, in those with lower education
and in those without employment. In Takeda et al.’s survey
and Potter et al.’s cohort study on 2,863 French women,
there was no association with advanced age, whereas in
several other studies, age dependency could not be analysed
due to a narrow age range of the samples (Takeda et al.
2006; Potter et al. 2009). Cohen et al. found an association
with lower education, while Potter et al. did not. In Potter et
al.’s study, there was no association with employment
status, while Cohen et al.’s results with regard to employ-
ment contrasted with ours, as women not working outside
the home were less likely to meet criteria for PMDD.
In a cross-sectional population-based Swedish survey
focusing on associations between women’s general health
and employment status and work conditions, it was shown
that unemployed women and those exposed to job strain
had an increased odd ratio for a high level of common
symptoms (Krantz and Ostergren 2000). These findings can
be considered in line with our results and would support the
theory of a negative correlation between level of control
and perceived symptom severity.
Hormonal contraceptives
PMS was less likely in OC users in our study. Diverse
results have been reported of several studies investigating
the interaction of OC use and premenstrual syndrome.
Some earlier results suggested no benefits with regard to
mood symptoms or even a negative influence of OCs on
PMS, such as prolonged negative mood, whereas more
recent studies attributed a beneficial effect to OCs,
especially on physical premenstrual symptoms and prepa-
rations with third generation progestogens and drospirenone
showed even a positive effect on psychological symptoms
(Graham and Sherwin 1992; Bancroft and Rennie 1993;
Graham and Sherwin 1993; Oinonen and Mazmanian 2002;
Table 4 (continued)
Models including only groups of predictors Overall model
OR (95% CI) OR (95% CI)
PMS PMDD PMS (n=3,002) PMDD (n=3,094)
Physical activity
Active 1 1
Partially active 1.12 (0.88–1.43) 0.96 (0.63–1.48)
Inactive 1.25 (0.87–1.80) 1.59 (0.91–2.78)
Alcohol consumption
No consumption 1 1 1 1
Mild consumption 0.80 (0.63–1.02) 0.66* (0.44–1.00) 0.81 (0.62–1.05) 0.89 (0.56–1.41)
Moderate to severe consumption 0.54 (0.27–1.07) 0.63 (0.22–1.82) 0.54 (0.27–1.09) 0.60 (0.17–2.08)
Smoking status
No smoker 1 1 1 1
Ex-smoker 1.46* (1.10–1.96) 1.43 (0.84–2.41) 1.67** (1.22–2.27) 1.57 (0.89–2.75)
Current smoker 1.03 (0.79–1.35) 1.31 (0.84–2.05) 1.03 (0.77–1.38) 1.14 (0.69–1.89)
Psychotropic drug consumption
No consumption 1 1 1 1
Analgesics 1.45** (1.11–1.89) 1.57 (0.99–2.50) 1.44* (1.08–1.93) 1.20 (0.71–2.03)
Antidepressants only 1.93* (1.00–3.75) 3.23** (1.34–7.80) 1.10 (0.50–2.41) 1.72 (0.63–4.73)
Benzodiazepines only 3.71*** (2.32–5.96) 1.19 (0.37–3.88) 2.50** (1.44–4.34) 0.38 (0.09–1.66)
Antidepressants and benzodiazepines 3.04** (1.42–6.51) 9.97*** (4.80–20.70) 1.75 (0.73–4.17) 1.62 (0.57–4.60)
*p<0.05, **p<0.01, ***p<0.001
a A separate model was calculated to analyse the association with oral contraceptives since only women up to age 49 had to answer the respective questions;
these models included n=1,731 for PMS and n=1,793 for PMDD
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Kurshan and Neill Epperson 2006). Globally, OCs were
found to have little impact on the pattern and incidence of
menstrual symptoms (Ross et al. 2003). Whereas in a study
comparing women with and without adverse mood effects
from combined oral contraceptives (COCs), Segebladh et
al. found a significantly increased prevalence of mood
disorders and premenstrual syndrome in women with mood
effects under COCs (Segebladh et al. 2009). The existing
results suggest that the therapeutic effect of COCs,
imitating the natural ovarian cycle, is minor and that an
underlying vulnerability might have a stronger influence.
The partially beneficial effect could be explained by the
enhancement of patients’ feeling of control through COC-
induced cycle stability.
Health behaviour
Former but not current smoking was predictive for PMS.
Current smoking revealed to be associated with a higher
incidence of PMS in several former studies (Cohen et al.
2002; Wittchen et al. 2002). In Bertone-Johnson et al.’s case-
control study, smokers were 2.1 times as likely to develop
PMS as were never smokers, and women with onset of
smoking during adolescence were at highest risk (Bertone-
Johnson et al. 2008). High BMI was shown to be associated
with PMS in various studies as well; in our study, it was—
although not significantly—higher in women with a BMI of
30 or more (Masho et al. 2005; Potter et al. 2009).
Health status
Physical and psychological health status factors had the
strongest predictive power for PMS and especially for
PMDD in our study. This is in line with Wittchen et al.,
who demonstrated a high use of general health and mental
health services in women with PMDD (Wittchen et al. 2002).
Divergences in PMS and PMDD predictors
Predictors for PMS and PMDD were not identical in our
study. Consumption of antidepressants, consumption of
antidepressants and benzodiazepines, psychological distress
and presence of severe physical symptoms were predomi-
nantly associated with PMDD. This might be due to more
pronounced symptoms of women with PMDD, but favours
also the theory that women with psychiatric comorbidity,
namely depressive and anxiety disorders, are particularly
prone to PMDD (De Ronchi et al. 2005).
Strengths/limitations
The size and representativity of our population-based
sample is a strength of our study. With 66% of approached
people participating in the telephone interview and 77% of
those answering the questionnaire, the participation rate
was within the expected limits. It is likely, however, that
there was a higher prevalence of PMS or PMDD among
non-responders. Assessments of physical and psychological
health were based on self-report and were therefore entirely
subjective. Another limitation of our study is the fact that
the German-language PSST has only been piloted on a
limited German-speaking sample and has not yet been
thoroughly validated. With regard to marital status, the
Swiss Health Survey did not further differentiate the
category of unmarried women, thus no further distinction
was possible between women with or without a partner. As
the group of women of the category “unmarried” certainly
also included some women with a partner, the odds ratio for
“unmarried” in the sense of “single” women may in fact
even be higher; thus our finding might be a conservative
estimate. Only 3% of the large, population-based sample is
qualified for PMDD. As a consequence, the analysis of
determinants for PMDD was limited due to the small size
of several sub-samples, e.g., the prevalence of PMDD in
widows seemed high (12.5%), but resulted, in fact, from
just two cases.
Conclusion
Almost 15% of women of reproductive age in Switzerland
had premenstrual symptoms to an extent requiring treat-
ment; in 3%, the criteria for PMDD were met. Socio-
cultural factors such as age and affiliation to a particular
language region seem to determine the prevalence, percep-
tion and handling of PMS, pointing to differences in
vulnerability of various ethnic groups. We could demonstrate
that PMS is associated with consumption of psychoactive
medications. Considering the association with poor physical
health and high psychological distress, a broader underlying
vulnerability in women qualifying for PMDD must be
assumed and should be taken into account in clinical
management as well as in future research in this field.
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